Introduction
In America, rapid demographic and nutritional changes have taken place. The majority of countries in Latin America are in the third stage of epidemiological transition, 1 which is characterised by a predominance of non-transmissible chronic diseases and a sustained increase in mortality of cardiovascular origin. Life expectancy has increased in some countries: in some it is similar to that seen in the US and European countries. However, this demographic transition is not uniform for all Latin American countries, since there are considerable regional differences even within the same country. Since cardiovascular disease is one of the main causes of mortality, it is vital that the control of risk factors of atherosclerosis should be included in the aims of the health programmes of all Latin American countries, and in those of the health professionals, who handle and care for this group of people.
Lifestyle and cardiovascular risk factors
Negative changes in lifestyle have played a significant role in the last 25 years, exerting a negative influence on health and increasing the prevalence of obesity (O), metabolic syndrome (MS), type 2 diabetes mellitus (DM2) and other risk factors for cardiovascular disease. Many of these conditions are emerging early, even during childhood. For example, in a study conducted in 209 Brazilian university students, a sedentary lifestyle was found in 78.9% and elevated levels of total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) were found in 9.1% and 7.6% of the sample, respectively. 2 Low HDL-C was present in 8.6%, and high serum triglycerides (TG) in 16.2% of subjects studied, and 15.6% of the students were smokers. A positive family history of cardiovascular disease was observed in 19.6%.
In a similar study 3 conducted in Chile among 1,301 graduate students aged between 18 and 25 years, the situation was similar. The results were high TC in 29.2% of subjects studied, high LDL-C in 16.2%, low HDL-C in 5%, smoking in 46.1% and sedentary habits in 60.8% of the cases. By contrast, the figure for systemic hypertension was only 4.6% and 11% had a family history of cardiovascular disease. These results show the high prevalence of cardiovascular risk factors in Latin America, particularly in young populations. [4] [5] [6] Obesity Reports from the Pan American Health Organization (PAHO), the World Health Organization (WHO) and from other ministries of health indicate that obesity is on the rise in Latin American countries, particularly in urban regions, and that the rates are higher among those living in poverty. Nowadays obesity is considered an epidemic not only in Latin America, but worldwide. 7 Data from Argentina, Chile, Paraguay, Mexico, Peru and Colombia show that approximately 50% of the population is overweight (with a body mass index [BMI] between 25 and 30 kg/m 2 ) 8,9 and more than 15% of the population is obese with a BMI > 30 kg/m 2 . Obesity has a major impact on the main cardiovascular risk factors. In Mexico, obesity is more common in people over the age of 30 years and is more prevalent among women. 10 Among women of reproductive age in Mexico, 30.8% are overweight and 21.7% obese. The prevalence of overweight increases to 40% in women aged 40 to 59 years. The prevalence of abdominal obesity was 58.8% in women and 21% in men in this report. 10 A study conducted in Chile in 2003, showed that only 36.9% of the population had an 'appropriate' weight: 37.8% were overweight (43.2% of men and 32.7% of women) and 23% of the population were obese (19.4% of men and 27% of women). 11 These figures were 16.75% higher than those reported previously in the Carmen study conducted in Valparaíso in 1990, 12 which showed that 19.7% of the population had a BMI > 30 kg/m 2 . Data from three surveys conducted during the years 1975, 1989 and 1996 in Brazil, showed that in 1989 obesity and overweight levels were reported for 30% of women and 27.3% of men. 13 For the year 1996 an increase of 100% was observed in the prevalence of obesity among women aged 20 to 34 years. 14, 15 Two studies from Argentina, one conducted in Santa Fé and one in Cordoba, gave figures for overweight of 32.5% and 39.3% and for obesity of 26.8% and 23% in men and women, respectively. Therefore, in total it may be estimated that about 60% of the population have weight abnormalities that are detrimental to their general health. and 26%, and metabolic syndrome in 14.4% of women and 21% of men, respectively, in apparently healthy subjects with a mean age of 37 years. [17] [18] [19] In Venezuela, Campos et al., in a study including 306 men and 41 women, found that the men had higher levels of TG (47%) and TC (40%) with low levels of HDL (40%). 20 In women, the most common changes observed were high levels of TC (46%) and high serum LDL-C (51.2%). 7 Thus, cardiovascular risk factors in Latin America have a high and increasing prevalence, and obesity, metabolic syndrome and DM2 are on the rise, as has happened already in more developed countries. It is important to highlight the high prevalence of dyslipidaemia with a low HDL-C level, recognising that this profile is associated with DM2, sedentary lifestyle and tobacco use, that together increase the risks for major cardiovascular events. 17, 21 MS often precedes DM2 and features hyperinsulinaemia, insulin resistance and hyperglycaemia. In patients with insulin-resistant states, high triglycerides (TG), low serum HDL-C levels and high blood pressure are commonly found. In addition, hyperinsulinaemia contributes to increased cardiovascular risk by reduction in fibrinolysis and high plasminogen activator inhibitor-1 (PAI-1) levels, predisposing to thrombosis.
Diabetes
Along with the increase of obesity, the prevalence of type 2 diabetes (DM2) has also increased worldwide. In urban regions of Latin America, diabetes prevalence is around 7-8%, while in rural areas it is 1-2% for the majority of countries. This suggests that the different lifestyles among urban populations contribute to the prevalence of diabetes. According to the Latin American Diabetes Epidemiology Group, using WHO criteria, Bolivia 21 has a 2.7% prevalence in the population of El Alto, whereas in Santa Cruz the prevalence is 10.7%. In Lima, Peru it was detected in 7.6% of the population, whereas in Huaraz the prevalence was 1.3% (five to six times lower rates). 22 In Mexico, the estimated prevalence of DM2 according to a national health study from the year 2000 using ADA criteria (ENSA2000) 10 is 10.8%, which is similar to the prevalence observed in Bogotá, Lima and São Paulo. However, it is important to mention that populations in Mexico with greater economic development, such as Veracruz and Sinaloa, have a higher prevalence of diabetes of 14.2% and 16.1%, whereas places with lower economic development such as Zacatecas and Guanajuato exhibit prevalences for DM2 of 5.6% and 6.8%.
In Chile, the prevalence of DM2 in people younger than 44 years is 0.15%, but this increases to 9.4% in the population aged between 45 and 64 years and to 15.2% in individuals over 64 years of age.
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Hypertension A number of surveys have shown that there is a high prevalence of hypertension (using the definition of greater than 140/90 mmHg used by The Joint Committee for Hypertension VI and VII) in Latin America. In Uruguay, the prevalence is 34%. 4, 6 In Mexico it is about 30.7%, 10 in Chile is 33.7%, 11 whereas in Argentina the prevalence is about 29.9%. 8 In Brazil, hypertension was found in 31.6%. 9 As these figures show, about one third of the Latin American population over the age of 18 years has hypertension.
Tobacco use
The consumption of cigarettes per capita increased 20% in Latin America in the years 1970 to 1985. Among men 30-50% smoke and among women 10-30% smoke. Although tobacco use is relatively stable in adults and men, there has been an important increase in tobacco use among women and young people. Latin American populations still have a passive attitude to smoking and tobacco use and there are no strong policies against its use among many health offices, either.
The prevalence of tobacco use in Chile decreases with age, with rates falling from 55% in subjects under 25 years of age to 11% in those over 64 years. The consumption of tobacco was more common in those at higher socio-economic levels (45%) in comparison to those at low economic levels (with 31%). 23 The situation in Colombia was different since a higher prevalence of smoking was observed among illiterate subjects (39.5%) and lower prevalences in those with a secondary education (22.5%). In countries such as Chile, Argentina, Uruguay and Venezuela, the annual consumption of cigarettes per inhabitant is between 1,000 and 1,300. In Peru, the consumption of cigarettes is similar to the consumption in Bolivia and Ecuador. In Mexico, during the year 1998, 27.7% of the population between the ages of 12 and 65 years were smokers, representing more than 13 million inhabitants. 24 Smoking was most common among people between the ages of 18 and 29 years, 10% of adults in the general population were smokers. Some 61.4% started smoking before the age of 18 years and 2.1% started smoking even before they reached the age of 10 years.
In Argentina, surveys indicate that 40% of men and 20% of women reported tobacco use. 25 In Brazil in 1988 a survey revealed that 45.7% of physicians and 40% of nurses smoke. According to the data provided by the PAHO, the prevalence of cigarette smoking appears to be decreasing among men and increasing among women. The rates in men fell from 54% to 40% between 1971 and 1988, whereas among women they rose from 20% to 36%. The position is similar in countries such as Venezuela, where smoking has decreased from 48.6% to 41.8% between men whereas tobacco consumption has increased from 26.3% to 39.2% among women.
Sedentary lifestyles
In Latin America, more than half the population does not meet the minimum recommendation of performing at least 30 minutes physical activity daily five days a week. 21 In Peru, the percentage of the population that exercises regularly in the urban region is as low as 12.8% in men and 10.5% in women. 22 Some 78.1% of young people aged 15 to 19 years do not exercise. This rate declines to 46.2% in the age group 45 to 59 years, but rises again to 71.7% in those over 60 years of age.
In the CARMEN study in Chile, 84.6% of the population studied did not exercise regularly (72.8% of men and 94.1% of women) 12 and the National Health Survey in 2003 (in Chile) showed that 89% (91% of women and 88% of men) were sedentary. 10 Young students are also sedentary -60.8% and 70.9% in Chile and Brazil, respectively.
In Mexico, according to the Second National Nutritional Survey (ENN II), 84.2% of women do not exercise. Only 8.9% exercised on the day before the survey and 16.1% reported performing exercise regularly. In Argentina, it was observed that those under 50 years of age performed a greater amount of activity than those over 50 years (45.2% versus 33.7%). 17 On the other hand, men in general undertake more intense physical activity than women do.
Role and importance of HDL-C as a cardiovascular risk factor
Findings from epidemiological studies such as the Framingham Study 26 and the Münster Prospective Cardiovascular Study 27 established that low serum levels of HDL-C constitute an independent cardiovascular risk factor and are a predictor of coronary heart disease (CHD). The results of these and other studies suggest that HDL-C be recognised as a major cardiovascular risk factor in international treatment guidelines.
The Framingham study 26 showed a clear prognostic influence of low plasma HDL-C levels and an increase in cardiovascular morbidity and mortality in both men and women. The incidence of coronary disease was eight times higher in individuals with low HDL-C levels (< 35 mg/dL [0.91 mmol/L]) in comparison to individuals with HDL-C > 65 mg/dL (1.68 mmol/L). A meta-analysis, 28 including four prospective trials, confirmed these findings and showed that for every 1 mg/dL (0.26 mmol/L) of increase in plasma HDL-C levels, a reduction of 2-3% is observed in the risk of coronary artery disease. This occurs independently of other risk factors, including high LDL-C levels. Low HDL-C levels also correlated with an increase in the severity of CHD and with the number and extent of involvement of the coronary vessels. 29 Because of this evidence, HDL-C is considered as an important risk factor for cardiovascular disease. 30 Low plasma HDL-C levels are common in the Latin American population, as has been demonstrated by study findings in Chile, 11 where 39.3% of the population have HDL values below 40 mg/dL (1.03 mmol/L). In Mexico, information was obtained from 15,607 people aged between 20 and 69 years in the National Chronic Diseases Survey (ENEC, 1993). Analyses conducted in 2,256 people showed that about 50% of the samples had some abnormality in lipids. 31 Normal triglyceride levels with low levels of HDL was the abnormal lipid pattern most commonly identified (in 18.6% of the general population). This occurred in 22% of men versus 16% in women. In contrast, hypertriglyceridaemia with low levels of HDL was observed in 12.9% of the general population, with a greater frequency in males (20.9%). This type of change is related to an atherogenic pattern along with insulin resistance syndrome. In England, the 'Health Survey for England' of 1998 32 showed that 16.9% of men and 5.4% of women aged > 60 years had low serum levels of HDL-C < 35 mg/dL (0.91 mmol/L). A similar prevalence was observed in the PROCAM study. 27 Benefits observed from increasing serum HDL-C levels In interventional studies using lipid-lowering drugs such as lovastatin, for example, AFCAPS/TexCAPS, 33 an increase of 6% in HDL-C values was observed, and this was associated with a 37% reduction in the risk of a major coronary event. This effect was also observed in the 4S study using simvastatin, 34 the HPS (Heart Protection Study), 35 WOSCOPS (West of Scotland Coronary Prevention Study) 36 and LACS (Lipoprotein and Coronary Atherosclerosis Study). 37 The VA-HIT study demonstrated that treatment with gemfibrozil increased HDL-C and decreased TG levels with some effect on LDL-C. A reduction in risk for non-fatal MI or CHD death of 22%, and a reduction of 28% in stroke risk, were observed. 38 Medical management of low serum HDL-C levels There are various therapeutic strategies to modify lipids and raise low serum HDL-C levels. 39 Despite the evidence for HDL-C as an independent risk factor in atherosclerosis, the importance of low serum HDL-C values (< 40 mg/dL [1.03 mmol/L] in men and < 45 mg/dL [1.16 mmol/L] in women) has not been stressed enough. In general, physicians delay pharmacological therapies for this abnormality, and focus more commonly on other lipid-modifying therapies targeting LDL-C and triglycerides. 40 Non-pharmacological therapies for low HDL-C Lifestyle changes are used to promote health. Reducing smoking, increasing exercise, healthy diets with appropriate amounts of carbohydrates (50 to 60% of total calories), proteins and fats (10 to 15% of total calories) and maintenance of a BMI < 25 kg/m 2 , have a positive influence in elevating serum HDL-C levels, as well as reducing overweight, obesity and insulin resistance. ) with low HDL-C plasma levels, losing weight by exercise, diet or in combination with a drug prescription (orlistat, sibutramine, others) can increase serum HDL-C levels. These measures are also effective in genetically predisposed obese subjects or in those who have high triglyceride levels. The physiopathological mechanisms by which HDL-C levels are reduced in obesity are due to an increase in body fat and decrease in lipolysis. This raises the level of free fatty acids, which are subsequently taken up by the liver and favour the production of very low-density lipoprotein cholesterol (VLDL-C) and cholesterol-rich TG. When these lipoproteins are elevated, fatty acids and cholesterol interchange HDL particles, a phenomenon mediated through the enzyme cholesterol ester transfer protein (CETP). This process of interchange produces a marked reduction in serum HDL-C levels, a situation that can be corrected when overweight or obese individuals lose body weight. Lower plasma levels of fatty acids decrease the amount of VLDL produced by the liver and promote a rise in HDL-C levels. In various studies, it has been observed that serum HDL-C levels can increase between 20% and 40% through weight loss, particularly if this is associated with higher physical activity (at least 30 minutes physical activity daily five days a week). Unfortunately, overweight and obesity are now part of a culture of consumerism which makes it difficult to modify diet and physical activity in the long term and to maintain ideal weight (BMI between 20 and 25 kg/m 2 ).
Physical activity
Exercise is an important way to promote elevation of serum HDL-C levels, and is even more effective when performed regularly. Exercise improves insulin resistance in skeletal muscle and adipose tissue. This effect is independent of body weight or percentage of body fat. Exercise also reduces abdominal fat deposits and free fatty acids (which generally promote insulin resistance). Exercise reduces triglycerides, gluconeogenesis, tumour necrosis factor (TNF), interleukin 6 (IL-6) and PAI-1, all factors which encourage an increase in HDL-C.
The positive and beneficial effects of exercise on lipids are related to the quantity of exercise (at least 30 minutes physical activity daily five days a week) rather than the intensity. The effects of exercise show an increase of 7% in HDL-C, a reduction of 40% in TG and a 40% reduction in intermediate density lipoproteins (IDL). 41 
Pharmacological treatment
Many drugs have been used to improve and normalise the lipid profile, but unfortunately, most strategies have targeted only high levels of LDL-C rather than low levels of HDL-C. The different drugs used include statins, fibrates and nicotinic acid, alone or in combination. Some, but not all, statins moderately increase HDL-C.
Fibrates interact with the peroxisome proliferator-activated receptor (PPAR) by increasing the synthesis of apo A1 and promoting an increase of serum HDL-C levels. The fibrate acts as a ligand for this receptor and stimulates the cell nucleus to increase the transcription of genes related to the synthesis of apo A1.
The VA-HIT controlled study 38 showed a reduction in coronary events associated with the increase in serum HDL-C values. No changes were observed in LDL-C levels in the group treated with gemfibrozil, but there was a significant increase in HDL-C and a reduction in TG levels. The HDL increase was considered the main influence in the reduction of cardiovascular events. In the Helsinki Heart Study, 42 a reduction in cardiovascular events in the subgroup of patients with low HDL-C and high TG was observed. This was attributed to treatment with fibrates through an increase in HDL-C, since only marginal minimal changes were observed in LDL-C.
Of the drugs currently available, nicotinic acid (niacin) has the greatest capacity to increase serum HDL-C levels. Statins increase HDL levels by only 5-15% and fibrates by 10-15%, whereas niacin increases HDL-C by 30%. 43 In addition to increasing HDL-C, niacin reduces TG and LDL-C values and is the only agent capable of reducing lipoprotein (a). Niacin (nicotinic acid) has antithrombotic effects associated with an improvement in endothelial function, a reduction in inflammatory processes in the vascular wall and the promotion of stability of the atherosclerotic plaque. 40, 44, 45 There are three current formulations of niacin: an immediate-release (IR) form, a sustained or slow-release form (SR) and the most recently developed form, known as extendedor-prolonged-release (ER). IR niacin is mainly metabolised by conjugation with glycine to form nicotinuric acid. Among its most important side effects are flushing, redness and hot flushes, which in some cases may increase non-compliance with the prescription.
SR niacin is metabolised principally by a series of oxidation and reduction reactions, resulting in the production of nicotinamide and pyramides. Although this formulation provides less flushing, it has the drawback of being associated with hepatotoxicity.
The modern formulation of ER niacin was created for optimal release of nicotinic acid over the course of 8-12 hours. This formulation causes less flushing and less hepatotoxicity than the other formulations. Therefore, this extended-release niacin presentation is widely used in the treatment of dyslipidaemia associated with high TG and low HDL-C. To reduce side effects to a minimum, this product should be taken once daily, preferably at bedtime, with a small low-fat meal. The ingestion of alcoholic or hot beverages and spicy foods should be avoided before administration. If, despite these measures, flushing still occurs, the use of 325 mg of acetylsalicylic acid 30 minutes before taking ER niacin may suppress or minimise its occurrence. 46 In practice, less frequent and intense flushes occur with continued use of niacin.
One other practical recommendation is to uptitrate the ER niacin, starting with a dose of 500 mg per 24 hours and increasing the dose in increments of 500 mg every four weeks, up to the maximum dose between 1,500 mg and 2,000 mg in many individuals.
In the secondary prevention of cardiovascular disease, niacin reduces the risk of non-fatal myocardial infarction by 27%, and of cerebrovascular events by 24%, compared to placebo. Nine years after the end of this study, the mortality in patients with niacin was 11% lower than in patients who had not received niacin treatment. 37 Setting up the position statement A preliminary meeting was held on 24th and 25th October 2004 in São Paulo, Brazil, during the Latin American Diabetes Congress. Scientific experts in lipids with an interest in low HDL-C as a cardiovascular risk factor were invited to participate at this meeting. The following objectives were established during this meeting:
• To establish a group of experts from Latin America on the study of HDL-C • To elaborate a review of the literature on this subject, dividing this endeavour into four working groups with the intention of producing a publishable paper; and • To issue a position statement of this expert group on the role of HDL-C treatment in Latin America. It was decided to summarize all the work material for peer review and scientific evaluation from this group's position in a second review meeting. This meeting was held in Miami, Florida, US on 5th and 6th March 2005, during which the validation process was accepted by all the members of the group and a final position document was elaborated. Seventy-seven scientific arguments were submitted for consideration in relation to: the epidemiology of cardiovascular risk factors in Latin America; possible mechanisms of low HDL-C levels and its consequences; the process by which HDL-C provides cardiovascular protection; current goals in the treatment of dyslipidaemia; and non-pharmacological and pharmacological therapies available for correcting known serum HDL-C levels in Latin America.
The instrument comprised 77 items and a measurement system 47 that was used with a Likert scale for semiquantitative measurements. It had five possible responses: totally agree; more agree than disagree; neither agree nor disagree; more disagree than agree; and totally disagree. A unanimous agreement was considered to be present when 100% of respondents gave a single response option, a 'majority agreement' was considered to exist when 70% or more of the responses were along the same lines, for example, those who answered 'totally agree' plus those who answered 'more agree than disagree'. When there was a complete scattering in the responses, when agreement was not obtained in > 70% or when > 70% was reached in the neither agreement nor disagreement option, this was considered as a lack of agreement. Subsequently, the results were submitted for discussion, non-validated concepts were eliminated and the position document was compiled using those items that were agreed. An editorial group was created to include all the conclusions in a written document.
Results
Twenty participants attended this second meeting, six of whom attended for the first time. Of those present at the first session (sixteen) held in São Paulo Brazil, three participants were unable to attend the second meeting but they agreed with the recommendations and suggestions.
Of the 77 concepts considered for validation of their content, 74 (96.1%) were validated by approval of more than 70% of those present for each of the concepts approved. Only one argument (1.3%) was agreed unanimously, 73 (94.8%) involved a majority agreement. On three arguments (3.9%) there was no agreement.
Discussion HDL-C has been related to the capacity to prevent and correct endothelial dysfunction. Endothelial dysfunction plays a relevant role in the pathogenesis of atherosclerosis and it is manifest by reductions in the amount of nitric oxide (NO) available and by increased affinity for leucocytes. Endothelial cells in apoptosis are the principal provider of thrombogenic elements and are a rich source of cytokines and oxygen free radicals, known to promote and exacerbate the inflammatory process in the endothelial cells. 40 Plasma levels of HDL-C have been shown to be an independent predictor of NOdependent peripheral vasodilatation, both in healthy individuals and in patients with hyperlipidaemia, diabetes, metabolic syndrome or coronary disease. HDL-C has antiapoptotic effects on endothelial cells and inhibits TNF-alpha induced by molecular adhesion cells. Thus, to increase serum levels of HDL-C in patients with a moderate to high coronary risk is an important goal, whether or not LDL-C goals are achieved, since residual risks still persist. 44, 46 Niacin (nicotinic acid) has antithrombotic effects associated with improvements in endothelial function and reduction of the inflammatory process in the vascular wall with stabilisation of the atherosclerotic plaque.
Combined therapy
Because it is difficult to achieve targets in dyslipidaemia with non-pharmacological medical therapies or with single pharmacological agents, combined pharmacological therapy has been widely used. This strategy seems to represent some advantage since a greater lipid-lowering effect may be achieved, but at the same time the risk of toxicity is increased. Since fibrates and statins have a limited effect in elevating low levels of HDL-C, the combination of these drugs plus niacin appears to be a logical approach.
Beneficial clinical effects have been observed from the combination of nicotinic acid (niacin) with simvastatin in patients with established coronary heart disease. In the HATS study, a reduction in LDL-C values of 42% and an increase of HDL-C of 26% was demonstrated. 44 In the ARBITER 2 study, 48 which included the combination of nicotinic acid plus statin for 12 months in patients with a high risk for CHD, an elevation of HDL-C of 21% and a reduction in triglycerides of 13% were detected. Little effect on LDL-C was observed. Whereas atherosclerosis progressed significantly with statin monotherapy, this was not the case with the combination of niacin and statins.
Niacin has also been used in combination with fibrates. In the Stockholm IHD study, 49 the combination of niacin with clofibrate was evaluated in post-myocardial infarction patients. After five years of follow-up, reductions of 26% in total mortality and 36% in fatal coronary disease were observed in the active treatment group compared to the control group.
Therapy with nicotinic acid in patients with diabetes
The dyslipidaemia observed in diabetic patients is mainly characterised by low plasma levels of HDL-C, high TG levels, a moderate increase in LDL-C and a clear predominance of small LDL particles. This profile has also been observed in patients with metabolic syndrome and insulin resistance with or without hypoglycaemia. Nicotinic acid has beneficial effects in three aspects of this lipid profile. It has been reported that niacin can slightly increase serum glucose levels. However, the results of the ADMIT 50 and ADVENT 51 studies show that extended-release niacin can be used safely in patients with diabetes. The ADMIT study included 125 diabetic patients with peripheral arterial disease. Patients had an increase of 29% in the HDL-C levels and a decrease in TG levels of 23%; glucose levels showed a slight increase, without any significant change in HbA 1C levels, during the 60 months of follow-up. 50 In the ADVENT study, 50, 51 patients with DM2 were studied and extended-release niacin was used as the main therapy. The changes observed in the lipid profile were similar to those produced by the ADVENT study with respect to HDL-C levels and TG. HbA 1C values did not show relevant clinical changes from baseline. Such changes can be tackled by adapting and modifying some of the regular medication for hyperglycaemia. or metabolic syndrome should be considered as individuals at high risk for cardiovascular disease. Therefore, in those patients with low HDL-C levels, it is recommended that niacin should be used in addition or in combination with statins or a fibrate. 3. It is broadly recommended in patients with dyslipidaemia and failure to respond to lifestyle therapies, that ER niacin should be added to the treatment with statins or fibrates to reach serum lipid goals. 4. It is recommended that ER niacin should be added as a secondary prevention therapy, in addition to statins or fibrates, in any patient who has dyslipidaemia and low HDL-C values. 5. It is suggested that gradual titration should be used in any patient receiving niacin, starting with 500 mg orally and uptitrating in increments of 500 mg every four weeks until the therapeutic dose is reached. 6. The prescription of exercise and a low-fat normocaloric diet should be recommended in every patient who has dyslipidaemia associated with low HDL-C and dyslipidaemia, whether overweight or not.
Recommendations

Suggestions
1.
It is suggested that, in patients who have dyslipidaemia with low HDL-C and in whom other cardiovascular risk factors are present, lipid markers should be closely monitored in order to reduce the global cardiovascular risk. 2. It is suggested that the consumption of alcoholic or hot beverages should be avoided 1-2 hours before taking niacin. 3. The use of 325 mg of acetylsalicylic acid is suggested 30 to 60 minutes before the administration of niacin in patients with manifestations of peripheral vasodilatation (known as flushing). 4. It is suggested that subjects receiving niacin should take it at bedtime, after supper or with a low-fat snack at nighttime. 5. In patients with DM or with metabolic syndrome, monitoring of serum glucose values is strongly suggested in view of the possibility of an increase in glucose levels. 6. It is suggested that, in any patient receiving niacin in addition to anticoagulants, the prothrombin time should be strictly monitored. 7. It is suggested that, in any patient with a predisposition to gout who suffers from hyperuricaemia and is taking niacin, special precautions should be taken in view of the potential increase in serum uric acid levels.
Conclusions
The demographic changes in Latin America have been associated with a greater life expectancy but changes in lifestyle have exerted a negative effect. Thus, a greater prevalence of chronic degenerative diseases such as obesity, metabolic syndrome, diabetes mellitus and dyslipidaemia has been detected in recent years. During the last decade the role of HDL-C as an independent cardiovascular risk factor has been put forward, and it requires a change in the management strategy of dyslipidaemia associated with low serum HDL-C levels.This approach looks primarily to reduce the residual risk of coronary disease, which still persists despite the achievements of other lipid-lowering approaches. We hope these recommendations will be useful to other physicians responsible for the care of patients with dyslipidaemia and low levels of HDL-C.
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